The systems biology of neurofibromatosis type 1 - Critical roles for microRNA

Experimental Neurology

Volumn 235, Issue 2, 2012, Pages 464-468

  Lee, Ming Jen ^a   Cho, Ji Hoon ^b   Galas, David J ^b   Wang, Kai ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

Gene module; Gene network; Malignant peripheral nerve sheath tumor; MicroRNA; Neurofibromatosis type 1; Systems biology; Transcription factor

Indexed keywords

GROWTH ASSOCIATED PROTEIN; IMATINIB; METHOTREXATE; MEVINOLIN; MICRORNA; NEUROFIBROMIN; PEGINTERFERON ALPHA2B; PIRFENIDONE; RAPAMYCIN; RAS PROTEIN; VINBLASTINE;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISEASE ASSOCIATION; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HUMAN; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOLECULAR GENETICS; MOLECULAR INTERACTION; NEUROFIBROMA; NEUROFIBROMATOSIS; NEUROFIBROMIN 1 GENE; NEUROPATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; TUMOR GROWTH;

ANIMALS; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; NEUROFIBROMATOSIS 1; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84860364109     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.10.023     Document Type: Review

References (46)

1. Balgobind B.V., Van Vlierberghe P., van den Ouweland A.M., Beverloo H.B., Terlouw-Kromosoeto J.N., van Wering E.R., Reinhardt D., Horstmann M., Kaspers G.J., Pieters R., Zwaan C.M., Van den Heuvel-Eibrink M.M., Meijerink J.P. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008, 111:4322-4328.
2. Behm-Ansmant I., Rehwinkel J., Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb. Symp. Quant. Biol. 2006, 71:523-530.
3. Chai G., Liu N., Ma J., Li H., Oblinger J.L., Prahalad A.K., Gong M., Chang L.S., Wallace M., Muir D., Guha A., Phipps R.J., Hock J.M., Yu X. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci. 2010, 101:1997-2004.
4. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., Arking D.E., Beer M.A., Maitra A., Mendell J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell. 2007, 26:745-752.
5. Cho J.H., Gelinas R., Wang K., Etheridge A., Piper M.G., Batte K., Dakhallah D., Price J., Bornman D., Zhang S., Marsh C., Galas D. Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Med. Genomics 2011, 4:8.
6. Dang J.D., Cohen P.R. Segmental neurofibromatosis and malignancy. Skinmed 2010, 8:156-159.
7. de Bruin A., Maiti B., Jakoi L., Timmers C., Buerki R., Leone G. Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J. Biol. Chem. 2003, 278:42041-42049.
8. Demestre M., Herzberg J., Holtkamp N., Hagel C., Reuss D., Friedrich R.E., Kluwe L., Von Deimling A., Mautner V.F., Kurtz A. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J. Neurooncol. 2010, 98:11-19.
9. Easton D.F., Ponder M.A., Huson S.M., Ponder B.A. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 1993, 53:305-313.
10. Endo-Munoz L., Dahler A., Teakle N., Rickwood D., Hazar-Rethinam M., Abdul-Jabbar I., Sommerville S., Dickinson I., Kaur P., Paquet-Fifield S., Saunders N. E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation. Cancer Res. 2009, 69:1800-1808.
11. Evans D.G., Baser M.E., McGaughran J., Sharif S., Howard E., Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 2002, 39:311-314.
12. Goldstein J., Lifshitz T. Myxoma of the nerve sheath. Report of three cases, observations by light and electron microscopy and histochemical analysis. Am. J. Dermatopathol. 1985, 7:423-429.
13. Gripp K.W., Hopkins E., Doyle D., Dobyns W.B. High incidence of progressive postnatal cerebellar enlargement in Costello syndrome: brain overgrowth associated with HRAS mutations as the likely cause of structural brain and spinal cord abnormalities. Am. J. Med. Genet. A 2010, 152A:1161-1168.
14. Gutmann D.H., Zhang Y., Hirbe A. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Ann. Neurol. 1999, 46:777-782.
15. Hager C.M., Cohen P.R., Tschen J.A. Segmental neurofibromatosis: case reports and review. J. Am. Acad. Dermatol. 1997, 37:864-869.
16. Harder A., Rosche M., Reuss D.E., Holtkamp N., Uhlmann K., Friedrich R., Mautner V.F., von Deimling A. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. Eur. J. Cancer 2004, 40:2820-2828.
17. He X., He L., Hannon G.J. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res. 2007, 67:11099-11101.
18. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17:193-199.
19. Hummel T.R., Jessen W.J., Miller S.J., Kluwe L., Mautner V.F., Wallace M.R., Lazaro C., Page G.P., Worley P.F., Aronow B.J., Schorry E.K., Ratner N. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin. Cancer Res. 2010, 16:5048-5057.
20. Huson S.M., Acosta M.T., Belzberg A.J., Bernards A., Chernoff J., Cichowski K., Gareth Evans D., Ferner R.E., Giovannini M., Korf B.R., Listernick R., North K.N., Packer R.J., Parada L.F., Peltonen J., Ramesh V., Reilly K.M., Risner J.W., Schorry E.K., Upadhyaya M., Viskochil D.H., Zhu Y., Hunter-Schaedle K., Giancotti F.G. Back to the future: Proceedings from the 2010 NF Conference. Am. J. Med. Genet. A 2011, 155:307-321.
21. Ideker T., Galitski T., Hood L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2001, 2:343-372.
22. Jung E.G. Segmental neurofibromatosis (NF-5). Neurofibromatosis 1988, 1:306-311.
23. Kayes L.M., Burke W., Riccardi V.M., Bennett R., Ehrlich P., Rubenstein A., Stephens K. Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am. J. Hum. Genet. 1994, 54:424-436.
24. Kolanczyk M., Mautner V., Kossler N., Nguyen R., Kuhnisch J., Zemojtel T., Jamsheer A., Wegener E., Thurisch B., Tinschert S., Holtkamp N., Park S.J., Birch P., Kendler D., Harder A., Mundlos S., Kluwe L. MIA is a potential biomarker for tumor load in neurofibromatosis type 1. BMC Med. 2011, 9:82.
25. Kurtz A., Martuza R.L. Antiangiogenesis in neurofibromatosis 1. J. Child Neurol. 2002, 17:578-584. (discussion 602-604, 646-651).
26. Lai E.C., Wiel C., Rubin G.M. Complementary miRNA pairs suggest a regulatory role for miRNA:miRNA duplexes. RNA 2004, 10:171-175.
27. Lammens T., Li J., Leone G., De Veylder L. Atypical E2Fs: new players in the E2F transcription factor family. Trends Cell Biol. 2009, 19:111-118.
28. Lee M.J., Stephenson D.A. Recent developments in neurofibromatosis type 1. Curr. Opin. Neurol. 2007, 20:135-141.
29. Lee M.J., Su Y.N., You H.L., Chiou S.C., Lin L.C., Yang C.C., Lee W.C., Hwu W.L., Hsieh F.J., Stephenson D.A., Yu C.L. Identification of forty-five novel and twenty-three known NF1 mutations in Chinese patients with neurofibromatosis type 1. Hum. Mutat. 2006, 27:832.
30. Ling B.C., Wu J., Miller S.J., Monk K.R., Shamekh R., Rizvi T.A., Decourten-Myers G., Vogel K.S., DeClue J.E., Ratner N. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005, 7:65-75.
31. Liu M.T., Su J.S., Huang C.Y., Tsai S.F. Novel mutations involving the NF1 gene coding sequence in neurofibromatosis type 1 patients from Taiwan. J. Hum. Genet. 2003, 48:545-549.
32. Menko F.H., Kaspers G.L., Meijer G.A., Claes K., van Hagen J.M., Gille J.J. A homozygous MSH6 mutation in a child with cafe-au-lait spots, oligodendroglioma and rectal cancer. Fam. Cancer 2004, 3:123-127.
33. Menon A.G., Gusella J.F., Seizinger B.R. Progress toward the isolation and characterization of the genes causing neurofibromatosis. Brain Pathol. 1990, 1:33-40.
34. Moore B.D., Denckla M.B. Neurofibromatosis. Textbook of Pediatric Neuropsychology: Research, Theory, and Practice 2000, 149-170. Guilford Press, New York, NY. K.O. Yeates, M.D. Ris, H.G. Taylor (Eds.).
35. Muram-Zborovski T.M., Stevenson D.A., Viskochil D.H., Dries D.C., Wilson A.R., Rong M. SPRED 1 mutations in a neurofibromatosis clinic. J. Child Neurol. 2010, 25:1203-1209.
36. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 1988, 45:575-578.
37. Ostergaard J.R., Sunde L., Okkels H. Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6. Am. J. Med. Genet. A 2005, 139A:96-105. (discussion 196).
38. Pasmant E., Sabbagh A., Hanna N., Masliah-Planchon J., Jolly E., Goussard P., Ballerini P., Cartault F., Barbarot S., Landman-Parker J., Soufir N., Parfait B., Vidaud M., Wolkenstein P., Vidaud D., France R.N. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J. Med. Genet. 2009, 46:425-430.
39. Rasmussen S.A., Friedman J.M. NF1 gene and neurofibromatosis 1. Am. J. Epidemiol. 2000, 151:33-40.
40. Reimer D., Sadr S., Wiedemair A., Stadlmann S., Concin N., Hofstetter G., Muller-Holzner E., Marth C., Zeimet A.G. Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin. Cancer Res. 2007, 13:144-151.
41. Rosser T.L., Packer R.J. Neurocognitive dysfunction in children with neurofibromatosis type 1. Curr. Neurol. Neurosci. Rep. 2003, 3:129-136.
42. Spurlock G., Griffiths S., Uff J., Upadhyaya M. Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam. Cancer 2007, 6:463-471.
43. Staser K., Yang F.C., Clapp D.W. Mast cells and the neurofibroma microenvironment. Blood 2010, 116:157-164.
44. Staser K., Yang F.C., Clapp D.W. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells. Curr. Opin. Hematol. 2010, 17:287-293.
45. Subramanian S., Thayanithy V., West R.B., Lee C.H., Beck A.H., Zhu S., Downs-Kelly E., Montgomery K., Goldblum J.R., Hogendoorn P.C., Corless C.L., Oliveira A.M., Dry S.M., Nielsen T.O., Rubin B.P., Fletcher J.A., Fletcher C.D., van de Rijn M. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J. Pathol. 2010, 220:58-70.
46. Yang F.C., Ingram D.A., Chen S., Zhu Y., Yuan J., Li X., Yang X., Knowles S., Horn W., Li Y., Zhang S., Yang Y., Vakili S.T., Yu M., Burns D., Robertson K., Hutchins G., Parada L.F., Clapp D.W. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 2008, 135:437-448.